Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
about
Macrophage Migration Inhibitory Factor as an Emerging Drug Target to Regulate Antioxidant Response Element SystemPreparedness and Cancer-Related Symptom Management among Cancer Survivors in the First Year Post-Treatment.Nuclear Factor (Erythroid-Derived 2)-Like 2 and Thioredoxin-1 in Atherosclerosis and Ischemia/Reperfusion Injury in the Heart.Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease.Role of Nuclear Factor Erythroid 2-Related Factor 2 in Diabetic Nephropathy.Effects of exercise on brain functions in diabetic animal models.Activation of NRF2 Signaling in HEK293 Cells by a First-in-Class Direct KEAP1-NRF2 Inhibitor.Bardoxolone Methyl Prevents High-Fat Diet-Induced Colon Inflammation in Mice.Analysis of risk factors and their interactions in type 2 diabetes mellitus: A cross-sectional survey in Guilin, China.The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction.Designing drugs that combat kidney damage.Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease.Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine.Novel investigational therapies for treating pulmonary arterial hypertension.Expression of the NRF2 Target Gene NQO1 Is Enhanced in Mononuclear Cells in Human Chronic Kidney Disease.Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management.An overview of the mechanisms and novel roles of Nrf2 in cardiovascular diseases.The conundrums of chronic kidney disease and aging.Heart Rate Variability as Early Biomarker for the Evaluation of Diabetes Mellitus Progress.Nrf2, the Master Regulator of Anti-Oxidative Responses.Nrf2 at the Heart of Oxidative Stress and Cardiac Protection.PGC1α in the kidney.Bardoxolone-the Phoenix?Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial.Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.Insulin Inhibits Nrf2 Gene Expression via Heterogeneous Nuclear Ribonucleoprotein F/K in Diabetic Mice.Nitrolipids in kidney physiology and disease.
P2860
Q28817936-431A2ADC-516C-4B31-93E0-4E5B7A7F3C94Q30151328-8E787E3F-0777-46D3-8438-E98C2023B254Q30275291-F3E997AA-CDAC-4332-9AE2-E10F4DA80908Q33633674-B6A0451D-5B85-4B5F-81D0-DF482FF011B4Q33645497-4FFB9D8B-EE25-4FCD-9C9B-B8717DE5AE58Q35613905-F182B830-1D01-42FF-B686-672CA7B9DB25Q36463474-313BC8F3-C475-4AC2-AD15-B0F8C90ECDF9Q36756653-CAA2B483-74AB-4B0A-B34E-5F034EFB890CQ37677869-1DB10445-123C-4136-BD14-6B96C7B44456Q37679215-3FAA286F-9329-4325-B952-386EA0320796Q38404587-33EC1D49-DA91-4D79-96DA-1567633A9D31Q38415749-6AB69B28-2A8A-4DA0-B29E-D79101F7F743Q38553911-B150F024-F0F5-4513-9502-A59A67C8ED0CQ38612061-83EA517B-0954-4665-98B3-537DB282170CQ38635855-A8C8677C-EEC8-446C-841F-AE59C99C12D0Q38786854-A9345102-833B-422E-ACB5-79F07B0D175FQ38906256-25406A9C-0052-4488-B09D-6AF04F145FE4Q38984573-3571242C-4277-44B7-8D98-BC7953DB7583Q39019320-1FCDC4D5-1515-4796-BB1C-FE758D3A1432Q40744075-D2B4F2DB-E38D-4C10-8E95-F698986DAF19Q47250925-F0150A6E-4455-4449-88DD-7BC23ADB68CCQ47350229-30C0B2E3-E19B-4B75-AF6D-1DF6C0AED987Q47938445-AF97B12C-5D5C-4D27-915E-240B78D8A8E1Q49680688-5B692D05-DCCE-4C12-B74F-1CF3818DFD39Q49835011-E637CB0F-241F-49E5-AE32-4E40C144808BQ50198506-B8318397-F3BB-4314-878B-8CF34C2DB78FQ51092133-BF8761DD-720A-450F-97BA-221DDC0FE3AAQ52722537-92EE8990-FF64-4064-B0CC-DD378D510E81
P2860
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Risk factors for heart failure ...... eated with bardoxolone methyl.
@en
Risk factors for heart failure ...... eated with bardoxolone methyl.
@nl
type
label
Risk factors for heart failure ...... eated with bardoxolone methyl.
@en
Risk factors for heart failure ...... eated with bardoxolone methyl.
@nl
prefLabel
Risk factors for heart failure ...... eated with bardoxolone methyl.
@en
Risk factors for heart failure ...... eated with bardoxolone methyl.
@nl
P2093
P1476
Risk factors for heart failure ...... eated with bardoxolone methyl.
@en
P2093
Angie Goldsberry
Colin J Meyer
Danielle Wrolstad
Dick de Zeeuw
George L Bakris
Glenn M Chertow
Melanie P Chin
Peter A McCullough
Peter G Linde
P304
P356
10.1016/J.CARDFAIL.2014.10.001
P577
2014-10-13T00:00:00Z